Skip to main content

Table 5 Performance of CRP as a biomarker for endometriosis

From: A high sensitivity assay is more accurate than a classical assay for the measurement of plasma CRP levels in endometriosis

Authors

Type of study

Controls

Endometriosis

Methodology

Results

Abrao

et al., 1997

Case-control study

N = 15

Time 1

Menstrual phase μg/ml:

1.58 ± 0.31

Time 2:

Proliferative phase μg/ml:

1.53 ± 0.33

N = 35

Stage I-II = 20

Stage III-IV = 15

Menstrual phase μg/ml:

Stage I-II: 5.06 ± 1.32

Stage III-IV: 13.15 ± 2.55

Proliferative phase μg/ml:

Stage I-II: 2.89 ± 0.59

Stage III-IV: 3.52 ± 0.41

Serum

Laparoscopically confirmed or excluded endometriosis

Menstrual and Proliferative phases of cycle

Home-made ELISA

Difference: Time1-Time 2

Controls: 0.05 ± 0.38

Stage I-II: 2.17 ± 1.16

Stage III-IV: 9.63 ± 2.34

Increased levels of CRP in endometriosis (especially for stages III-IV)

Lermann

et al., 2010

Prospective nonrandomized controlled trial

N = 34

CRP: 2.88 ± 2.79 ng/ml

hsCRP: 2.48 ± 3.77 ng/ml

N = 48

Stage I: 7

Stage II: 5

Stage III: 18

Stage IV: 18

CRP: 3.54 ± 3.24

hsCRP: 3.61 ± 4.82

Serum

Laparoscopically confirmed or excluded endometriosis

Early Proliferative cycle phase

CRP and hsCRP methods (details Not Available)

NS differences

Matarese

et al., 2000

Case-control study

N = 15

N = 13

Stage I-II: 7

Stage III-IV: 6

Serum

Laparoscopically confirmed or excluded endometriosis

Proliferative and secretive cycle phase

N Latex CRP monokit (Bering Nephelometer Systems)

CRP serum concentrations were less than 3.5 mg/L in all subjects

Mihalyi

et al., 2010

Case-control study

N = 93

All phases:

0.64 (0.11-15.03) mg/L

Secretory phase

0.56 (0.11-14.14) mg/L

N = 201

All phases

Stage III-IV:

1.35 (0.23-34.78) mg/L

Secretory phase

Stage I-IV:

0.88 (0.12-27.23) mg/L

EDTA Plasma

Laparoscopically confirmed or excluded endometriosis

Menstrual, Proliferative and Secretory phases

hsCRP method: HS Tina-quant CRP (latex) hs assay (Roche, Vilvoorde, Belgium)

Significant increase in Stage III-IV (independent of cycle phase and in the luteal phase (p < 0.0001; p = 0.001respectively)

Significant increase in Stage I-IV of endometriosis in the luteal phase (p = 0.03)

Xavier

et al., 2005

Case-control study

N = 13

Early proliferative:

0.68 (0.19-2.22) mg/L

Late proliferative:

0.59 (0.21-1.28) mg/L

Early secretory:

0.90 (0.42-2.31) mg/L

Late secretory:

0.87 (0.22-1.52) mg/L

N = 25

Stage III-IV

Early proliferative:

2.29 (0.70-3.54) mg/L

Late proliferative:

1.10 (0.30-2.06) mg/L

Early secretory:

1.09 (0.39-2.62) mg/L

Late secretory:

0.60 (0.28-3.19) mg/L

Serum

Early and late Proliferative phase

Early and late Secretory phase

hsCRP two-site homemade ELISA

NS differences